EN PL

News

FDA: ICH Q3C Maintenance Procedures for the Guidance for Industry Q3C Impurities: Residual Solvents

04.08.2010
Draft Recommendation for the Revision of the Permitted Daily Exposure for Cumene According to the Maintenance Procedures for Q3C Impurities: Residual Solvents ...

FDA: The Radioactive Drug Research Committee: Human Research Without An Investigational New Drug Application

04.08.2010
This guidance is intended to provide information for those using radioactive drugs for certain research purposes to help determine whether research studies can be conducted under 21 CFR 361.1, ...

FDA: Label Comprehension Studies for Nonprescription Drug Products

04.08.2010
The Food and Drug Administration (FDA) sometimes requires sponsors to conduct label comprehension studies that are designed to evaluate proposed nonprescription drug product labeling. This ...

EMA: Scientific guideline: Questions & Answers: positions on specific questions addressed to the EWP therapeutic subgroup on pharmacokinetics

04.08.2010
In the context of assessment procedures, the Therapeutic Subgroup on Pharmacokinetics of the Efficacy Working Party (EWP-PK subgroup) is occasionally consulted by the CHMP or, following ...

EMA: Regulatory and procedural guideline: Centralised procedures and MRL procedures. Recommended submission dates for new and extension applications

04.08.2010
Centralised procedures and MRL procedures Recommended submission dates for new and extension applications ...

EMA: Scientific guideline: Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg)

04.08.2010
This Guideline describes the information to be documented when an application is made for a marketing authorisation for a human normal immunoglobulin for intravenous use (IVIg). The guidance ...

EMA: Clinical efficacy and safety: Radiopharmaceuticals and Diagnostic Agents

04.08.2010
Clinical efficacy and safety: Radiopharmaceuticals and Diagnostic Agents ...

EMA: Safety monitoring of medicines: overview of the Agency’s activities

19.07.2010
Before a medicine is authorised for use, any experience of its safety and efficacy is limited to its use in clinical trials. Therefore, at the time of a medicine’s authorisation, it will only ...

EMA: Scientific guideline: ICH: Q 3 C (R4): Impurities: Residual solvents - Step 5, adopted

19.07.2010
The objective of this guideline is to recommend acceptable amounts for residual solvents in pharmaceuticals for the safety of the patient. The guideline recommends use of less toxic solvents and ...

EMA: Reflection paper on quality, non-clinical and clinical issues related to the development of recombinant adeno-associated viral vectors

19.07.2010
The aim of this paper is to discuss quality, non-clinical and clinical issues that should be considered during the development of medicinal products derived from AAV, and to indicate requirements ...